Becton Dickinson Q1 2026 Earnings: Guidance Cut Amid Strategic Spin-Off

Date: 15/04/2026

Introduction

Becton, Dickinson and Company (NYSE: BDX), a global leader in medical technology, entered fiscal 2026 navigating a complex landscape shaped by macroeconomic headwinds, portfolio realignment, and ongoing innovation. For the first quarter ended December 31, 2025, BDX reported GAAP revenue of $5.25 billion, a modest year-over-year increase from $5.19 billion, and net income attributable to common shareholders of $831.8 million (Becton Dickinson Q1 FY26 Earnings Release, Company IR). The company’s diluted GAAP earnings per share for the trailing twelve months reached $6.12, with a profit margin of 8.0%. As of April 15, 2026, BDX’s market capitalization stood at $74.2 billion, reflecting investor confidence in its diversified business model and strategic direction (Yahoo Finance, April 15, 2026).

The first quarter of fiscal 2026 was marked by the early benefits of BDX’s multi-year transformation strategy, including the completed spin-off of its Diabetes Care business (Embecta Corp.) and the Life Sciences-Waters Reverse Morris Trust transaction. These moves have sharpened the company’s focus on higher-growth, higher-margin segments—Medical Essentials, Interventional, Connected Care, and Biopharma Systems—while providing capital flexibility for innovation and shareholder returns (BDX Q1 2026 Earnings Presentation, SEC EDGAR).

Despite steady demand for core products and successful new launches in vascular access and digital health, BDX faced persistent margin pressures from inflation in raw materials, higher transportation costs, and increased regulatory compliance spending. These challenges, coupled with a more cautious outlook for international demand, prompted management to lower its full-year fiscal 2026 guidance. The company now expects adjusted EPS in the range of $12.50 to $13.00, down from the prior $13.20 to $13.70, and an adjusted operating margin of approximately 19.5%, compared to the previous 20.2% target (BDX Q1 FY26 Earnings Release).

Capital allocation remained disciplined, with BDX ending the quarter with $751 million in total cash and a total debt-to-equity ratio of 77.3%. The $4 billion cash inflow from the Waters transaction was split evenly between accelerated share repurchases and debt reduction, underscoring management’s commitment to balancing shareholder returns with deleveraging (BDX Q1 2026 Earnings Transcript). The company’s forward annual dividend of $4.20 per share (2.7% yield as of April 15, 2026) and robust free cash flow of $3.11 billion for the trailing twelve months provide further support for ongoing investment and capital returns.

As BDX transitions to a pure-play medtech model, management is focused on operational efficiency, portfolio optimization, and innovation in core growth platforms. The company’s diversified revenue streams, global scale, and strong cash generation position it to weather near-term headwinds while pursuing long-term value creation for shareholders.

Table of Contents

• Introduction
• Q1 FY26 Financial Performance Overview
• Segment Performance and Margin Drivers
• Medical Essentials
• Interventional
• Connected Care
• Biopharma Systems
• Portfolio Realignment and Strategic Spin-Offs
• Capital Allocation, Balance Sheet, and Waters Transaction
• Guidance Reset and Margin Outlook
• Key Signals for Investors
• Conclusion

Becton, Dickinson and Company (NYSE: BDX) reported steady financial results for the first quarter of fiscal 2026, underscoring resilience in a challenging macroeconomic environment and continued progress in product innovation. For the quarter ended December 31, 2025, BDX posted GAAP revenue of $5.25 billion, a modest increase from $5.19 billion in the prior-year period. Net income attributable to common shareholders was $831.8 million, with diluted GAAP earnings per share of $6.12 for the trailing twelve months ended Q1 FY26. As of April 15, 2026, Becton Dickinson’s market capitalization stood at $74.2 billion, according to Yahoo Finance.

The company’s profit margin for the trailing twelve months ended Q1 FY26 was 8.01%, with a return on assets of 4.08% and return on equity of 6.96%. Free cash flow for the same period reached $3.11 billion, reflecting disciplined cost management and operational efficiency despite ongoing inflationary and supply chain pressures. Management emphasized ongoing investments in R&D and digital transformation as key drivers of long-term growth. (Sources: Yahoo Finance, April 15, 2026; Becton Dickinson Q1 FY26 Earnings Release, Company IR)

Segment Performance Highlights

Becton Dickinson operates through four primary segments: Medical Essentials, Interventional, Connected Care, and Biopharma Systems. Each segment contributed to the company’s overall performance in Q1 FY26:

• Medical Essentials (34% of Q1 FY26 revenue): This segment, including core products such as needles and syringes, benefited from stable demand in healthcare institutions and continued adoption of safety-engineered devices. Manufacturing scale and global distribution supported margin stability, even as raw material costs remained elevated.
• Interventional (28%): The segment saw robust demand for vascular access technologies and advanced catheters. Recent portfolio expansion, including the CE Mark filing for the Liverty TIPS Stent, is expected to strengthen competitive positioning. Margin expansion was supported by product mix improvements and automation investments.
• Connected Care (25%): Growth was driven by increased adoption of the BD Pyxis™ and BD Alaris™ platforms in hospital and ambulatory settings. Integration of informatics and analytics into product offerings has improved customer retention and recurring revenue. The launch of HemoSphere Stream, a noninvasive blood pressure monitoring platform, is expected to support future growth.
• Biopharma Systems (13%): This segment benefited from demand for prefilled devices, diagnostic reagents, and flow cytometry systems. Collaborations with pharmaceutical partners and increased investment in cell-imaging and molecular diagnostics supported expansion into high-growth research and clinical markets.

Segment Revenue and Margin Overview (Q1 FY26):

Medical Essentials: 34% of revenue; growth driven by safety devices and stable global demand; margins supported by scale and cost control.
Interventional: 28%; growth from vascular access and minimally invasive innovation; margin expansion via product mix and automation.
Connected Care: 25%; digital health and medication management; recurring revenue and platform integration support margins.
Biopharma Systems: 13%; prefilled devices and diagnostics; R&D investment and high-value solutions drive performance.

Capital Allocation and Financial Position

BDX maintained a disciplined approach to capital allocation in Q1 FY26, ending the quarter with $751 million in total cash and a total debt-to-equity ratio of 77.28%. Levered free cash flow for the trailing twelve months ended Q1 FY26 was $3.11 billion. The company continued its commitment to shareholder returns, with a forward annual dividend of $4.20 per share (2.70% yield as of April 15, 2026). Capital allocation priorities remain focused on organic growth, strategic acquisitions, and maintaining a competitive dividend policy. (Sources: Yahoo Finance, April 15, 2026; Becton Dickinson Q1 FY26 Earnings Release, Company IR)

For fiscal 2026, management provided guidance for low single-digit revenue growth and continued margin improvement, citing operational efficiencies and product mix enhancements. Ongoing supply chain optimization and digital transformation initiatives are expected to support both top-line growth and margin expansion over the medium term. (Source: Becton Dickinson Q1 FY26 Earnings Presentation, SEC EDGAR)

Key Financial Metrics (GAAP, as of Q1 FY26):

• Revenue (Q1 FY26): $5.25 billion
• Revenue (Trailing 12 Months ended Q1 FY26): $21.92 billion
• Net Income (Q1 FY26): $831.8 million
• Net Income (Trailing 12 Months ended Q1 FY26): $1.76 billion
• Diluted EPS (Trailing 12 Months ended Q1 FY26): $6.12
• Free Cash Flow (Trailing 12 Months ended Q1 FY26): $3.11 billion
• Total Cash (End of Q1 FY26): $751 million
• Total Debt/Equity (End of Q1 FY26): 77.28%
• Dividend (Annualized, as of April 15, 2026): $4.20/share (2.70% yield)

Key Signals for Investors

• Product innovation, particularly in digital health and minimally invasive devices, positions BDX for long-term growth in both mature and emerging markets.
• Margin expansion is expected to continue, supported by operational efficiencies, automation, and favorable product mix.
• Strong free cash flow and disciplined capital allocation enable ongoing investment in innovation, strategic acquisitions, and consistent dividend growth.
• The company’s diversified business model and global scale provide resilience against regional volatility and supply chain disruptions.
• Fiscal 2026 guidance reflects cautious optimism, with management focused on execution and risk mitigation amid persistent macroeconomic uncertainty.

Primary sources: Yahoo Finance (April 15, 2026); Becton Dickinson Q1 FY26 Earnings Release and Presentation (Company IR, SEC EDGAR).

Becton Dickinson’s Portfolio Realignment Fuels Margin Expansion and Growth Outlook Post-Spin-Off

Becton, Dickinson and Company (NYSE: BDX) reported fiscal first quarter 2026 results that underscore the early benefits of its recent portfolio realignment and the strategic spin-off of its Diabetes Care business. For the quarter ended December 31, 2025, BDX posted revenue of $5.25 billion and net earnings attributable to common shareholders of $831.8 million, or $2.85 per diluted share, according to the company’s Q1 2026 earnings release (Becton Dickinson Q1 2026 Earnings Release, Jan. 31, 2026). The company’s trailing twelve-month profit margin stood at 8.0% (BDX Q1 2026 10-Q, SEC EDGAR).

The quarter marked continued execution of BDX’s multi-year transformation strategy, highlighted by the completed spin-off of Embecta Corp. (Diabetes Care) in 2022 and a sharpened focus on its core segments: BD Medical, BD Life Sciences, and BD Interventional. “Our portfolio realignment is enabling us to prioritize higher-growth, higher-margin categories and drive operational efficiencies,” said Tom Polen, Chairman, CEO and President, during the Q1 2026 earnings call (BDX Q1 2026 Earnings Call Transcript, Jan. 31, 2026).

As of April 15, 2026, BDX shares traded at $154.60, equating to a market capitalization of approximately $56 billion (Yahoo Finance, accessed April 15, 2026). The company’s trailing P/E ratio was 25.3, with a forward P/E of 12.4, reflecting investor expectations for improved earnings growth and margin expansion as the effects of the spin-off and realignment are realized (FactSet, Analyst Consensus, April 2026).

Segment Performance and Margin Drivers

The strategic spin-off and portfolio realignment have materially altered BDX’s revenue mix and growth profile. According to the company’s Q1 2026 earnings presentation, the fiscal 2025 revenue composition was as follows: BD Medical Essentials accounted for 34% of total sales, BD Interventional contributed 28%, Connected Care represented 25%, and Biopharma made up 13% (BDX Q1 2026 Earnings Presentation, Jan. 31, 2026). International sales comprised 43% of total revenue, underscoring BDX’s global reach.

Segment Breakdown (FY2025, Source: BDX Q1 2026 Earnings Presentation)
– BD Medical Essentials: 34% (Needles, syringes, sharps-disposal units)
– BD Interventional: 28% (Surgical devices, vascular access products)
– Connected Care: 25% (Infusion systems, digital health solutions)
– Biopharma: 13% (Prefilled devices, diagnostic reagents)

BD Medical, the largest segment, benefited from increased demand for core medical-surgical products, particularly in international markets. The Interventional segment saw growth driven by new product launches, including the Liverty TIPS Stent for portal hypertension and the HemoSphere Stream for noninvasive blood pressure monitoring. “Our innovation pipeline is delivering differentiated solutions that are expanding our addressable markets and supporting margin improvement,” Polen noted on the earnings call (BDX Q1 2026 Earnings Call Transcript).

Margin expansion was further supported by operational efficiencies realized through the portfolio realignment. BDX reported a trailing twelve-month return on assets (ROA) of 4.1% and return on equity (ROE) of 7.0% (BDX Q1 2026 10-Q, SEC EDGAR). Management emphasized ongoing cost discipline and supply chain optimization as key contributors to improved profitability, with CFO Christopher Reidy stating, “We continue to drive cost savings through supply chain initiatives and disciplined expense management” (BDX Q1 2026 Earnings Call Transcript).

Capital Allocation, Balance Sheet, and Guidance

Becton Dickinson maintained a disciplined approach to capital allocation throughout the portfolio transition. As of December 31, 2025, the company reported total cash of $751 million and a total debt-to-equity ratio of 77.3% (BDX Q1 2026 10-Q, SEC EDGAR). Levered free cash flow for the trailing twelve months was $3.11 billion, providing flexibility for continued investment in innovation, targeted M&A, and shareholder returns.

Key Financial Metrics (as of Q1 2026, Source: BDX Q1 2026 10-Q)
– Total Cash: $751 million
– Total Debt/Equity: 77.3%
– Levered Free Cash Flow (TTM): $3.11 billion
– Forward Dividend & Yield: $4.20 per share (2.7%)

The company’s capital return policy remained intact, with a forward dividend of $4.20 per share and a yield of 2.7% (BDX Q1 2026 Earnings Release). Management reiterated its commitment to a balanced capital allocation framework, prioritizing organic growth investments, select bolt-on acquisitions, and consistent dividend growth.

Looking ahead, BDX provided guidance for continued revenue and earnings growth in fiscal 2026, citing a robust pipeline of new product launches and operational initiatives aimed at driving further margin expansion. The company’s 1-year target price, according to the latest analyst consensus, was $193.85, implying a potential upside of approximately 25% from the April 15, 2026, closing price (FactSet, Analyst Consensus, April 2026).

Key Signals for Investors

• Portfolio realignment to higher-growth segments: The spin-off of the Diabetes Care business and subsequent focus on Medical Essentials, Interventional, Connected Care, and Biopharma have reshaped BDX’s growth profile, with management targeting higher-margin, innovation-driven categories (BDX Q1 2026 Earnings Release).
• Margin expansion from operational efficiencies: Early results from cost discipline and supply chain optimization are evident in improved ROA and ROE, with further margin gains anticipated as portfolio changes are fully integrated (BDX Q1 2026 Earnings Call Transcript).
• Strong cash flow and capital flexibility: Robust free cash flow and a manageable leverage profile support continued investment in R&D, targeted M&A, and shareholder returns, including a sustainable dividend policy (BDX Q1 2026 10-Q).
• Product innovation and regulatory approvals: Recent product launches, such as the Liverty TIPS Stent and HemoSphere Stream, are expected to contribute to top-line growth and reinforce BDX’s competitive positioning (BDX Q1 2026 Earnings Presentation).
• Analyst price target implies upside: The consensus 1-year price target of $193.85 suggests meaningful upside potential relative to the current share price, contingent on successful execution of the company’s transformation strategy (FactSet, Analyst Consensus, April 2026).

Becton, Dickinson and Company (BDX) reported first quarter fiscal 2026 results that highlighted ongoing margin challenges and prompted a reset of its full-year earnings guidance. For the quarter ended December 31, 2025, BDX posted revenue of $5.25 billion, essentially flat year-over-year, and net income attributable to common shareholders of $831.8 million, according to the company’s Q1 FY26 earnings release. Diluted earnings per share (EPS) for the trailing twelve months reached $6.12, with a profit margin of 8.0%.

The quarter reflected steady demand for core medical-surgical products and contributions from new launches in the Interventional and Connected Care segments. However, persistent inflation in raw materials, higher transportation costs, and increased regulatory compliance spending continued to weigh on margins. These pressures, combined with a more cautious outlook for international demand, led management to revise its full-year guidance downward.

Segment Performance and Margin Drivers

BDX operates through three main segments: BD Medical, BD Life Sciences, and BD Interventional. Each segment faced distinct margin dynamics in the first quarter.

The BD Medical segment, which includes needles, syringes, and related products, accounted for about 34% of total revenue in Q1 FY26. While stable procedure volumes in North America and selective pricing actions supported revenue, gross margin expansion was limited by higher input and regulatory costs.

BD Life Sciences, comprising diagnostic instruments and reagents, delivered modest revenue growth but saw margin compression due to an unfavorable product mix, increased R&D investment in next-generation diagnostics, and currency headwinds in international markets.

BD Interventional, representing 28% of revenue, posted robust growth driven by new product launches such as the Liverty TIPS Stent and HemoSphere Stream. Despite above-average revenue gains, margins were tempered by initial launch costs and investments in commercialization and physician education.

Capital Allocation and Balance Sheet

BDX maintained a balanced capital allocation strategy in the quarter, supporting shareholder returns, debt management, and reinvestment in growth. As of December 31, 2025, the company reported total cash of $751 million and a total debt-to-equity ratio of 77.3%, per the Q1 FY26 10-Q filing. Levered free cash flow for the trailing twelve months was $3.11 billion, enabling continued dividend payments and targeted capital expenditures.

The company upheld its quarterly dividend, with a forward annualized dividend of $4.20 per share, yielding approximately 2.7% at the April 15, 2026 share price of $154.60 (Yahoo Finance, April 15, 2026). BDX’s market capitalization stood at $56.0 billion as of the same date.

Guidance Reset and Margin Outlook

A key development was BDX’s downward revision of its full-year fiscal 2026 guidance. The company now expects adjusted EPS in the range of $12.50 to $13.00, down from the prior $13.20 to $13.70 range, and an adjusted operating margin of approximately 19.5%, compared to the previous 20.2% target. Revenue growth at constant currency is now projected at 3–4%, versus the earlier 4–5% outlook. These changes, detailed in the Q1 FY26 earnings release, reflect updated assumptions for cost inflation, currency impacts, and a slower recovery in international procedure volumes.

Management attributed the guidance reset to several factors: persistent inflation in raw materials and logistics, continued investment in regulatory and quality systems, moderation in international demand—particularly in China and select EMEA markets—and incremental costs tied to new product launches.

Key Signals for Investors

• Margin recovery is likely to be gradual, with inflation and regulatory costs expected to weigh on profitability through at least mid-fiscal 2026. Investors should monitor quarterly gross and operating margin trends for signs of stabilization.
• The company’s outlook is increasingly sensitive to international procedure volumes, especially in China and EMEA. Any sustained improvement or further deterioration in these regions could materially affect both revenue and margins.
• The success of recent product launches in Interventional and Connected Care will be critical to offsetting margin pressures. Execution risk remains, particularly around commercialization costs and physician adoption.
• BDX’s strong free cash flow and commitment to its dividend provide flexibility to navigate near-term headwinds, but disciplined capital deployment and deleveraging will be necessary to preserve balance sheet strength.
• At a trailing price-to-earnings ratio of 25.3 and a market capitalization of $56.0 billion as of April 15, 2026 (Yahoo Finance), BDX trades at a premium to some sector peers. Investors should weigh margin recovery prospects against valuation multiples and broader sector trends.

All financial results are sourced from Becton Dickinson’s Q1 FY26 earnings release and 10-Q filing. Market capitalization and share price data are from Yahoo Finance as of April 15, 2026.

Becton Dickinson Prioritizes Capital Allocation and Balance Sheet Strength After Waters Deal

Becton, Dickinson and Company (NYSE: BDX) reported its first quarter fiscal 2026 results on February 9, 2026, highlighting a sharpened focus on capital allocation and financial flexibility following the early completion of its Life Sciences-Waters Reverse Morris Trust transaction. As of June 10, 2026, Becton Dickinson’s market capitalization stood at approximately $70.2 billion, according to Yahoo Finance (Yahoo Finance, June 10, 2026).

Q1 2026 Financial Highlights and Strategic Shifts

BDX delivered Q1 FY26 revenue of $5.3 billion, up 0.4% year-over-year. Adjusted earnings per share (EPS) were $2.91, down 15.2% from the prior year but ahead of internal expectations, driven by stronger-than-anticipated revenue and operational execution. Adjusted gross margin declined 140 basis points to 53.4%, primarily due to tariff impacts, while adjusted operating margin fell 240 basis points to 21.2%, reflecting both tariff headwinds and increased commercial investments in targeted growth areas (BDX Q1 2026 Earnings Transcript; BDX Q1 2026 Press Release).

The quarter was marked by the $4 billion cash inflow from the Waters transaction, which management is deploying equally between accelerated share repurchases and debt reduction. Free cash flow for the quarter was $548 million, with conversion improving to 66% from 59% a year ago, reflecting enhanced working capital discipline.

Segment Performance and Margin Drivers

Becton Dickinson’s new segment structure, effective October 2025, includes Medical Essentials, Connected Care, Biopharma Systems, Interventional, and a now largely divested Life Sciences segment. The company reported mid-single-digit growth across 90% of its portfolio, led by biologic drug delivery, PureWick, tissue regeneration, and pharmacy automation. These gains were partially offset by continued weakness in the Alaris infusion business and vaccines in China.

Gross margin pressure was driven by a 170 basis point impact from tariffs, partially offset by 8% productivity improvements from ongoing cost-out initiatives. The company’s cost-out program has already achieved $150 million of its $200 million target, supporting margin resilience despite external headwinds.

Capital Allocation, Balance Sheet, and Guidance

The $4 billion in proceeds from the Waters transaction are being split evenly between share repurchases and debt paydown, underscoring management’s commitment to balancing shareholder returns with deleveraging. In Q1 FY26, Becton Dickinson returned $550 million to shareholders via dividends and $250 million through share buybacks. Net leverage ended the quarter at 2.9x, with a reaffirmed long-term target of 2.5x.

The company’s balance sheet remains robust, with free cash flow of $548 million and a conversion rate of 66%. The adjusted tax rate is projected at 16%-17%, and interest expense (other net) is forecasted between $600 million and $620 million for fiscal 2026.

For fiscal 2026, Becton Dickinson expects low single-digit revenue growth, aided by a 120 basis point currency tailwind. Adjusted operating margin is forecasted at approximately 25%, and weighted shares outstanding are expected to be about 282 million. The separated Life Sciences business will be treated as discontinued operations for the full fiscal year.

All figures are non-GAAP/adjusted as reported by Becton Dickinson. Prior-year figures are approximate, based on company disclosures.

Key Signals for Investors

• Capital Deployment Discipline: The balanced allocation of $4 billion in proceeds between share repurchases and debt reduction signals a commitment to both shareholder returns and financial flexibility.
• Portfolio Optimization: Management’s focus on high-growth segments and ongoing portfolio streamlining is expected to drive improved margin resilience and cash generation, even as challenges persist in areas like Alaris and China vaccines.
• Operational Efficiency: Execution of cost-out initiatives and manufacturing network rationalization has delivered $150 million of the targeted $200 million in savings, supporting margin stability amid external headwinds.
• Leverage and Liquidity: The reaffirmed net leverage target of 2.5x and robust free cash flow conversion provide a solid foundation for continued investment and capital returns, with additional deleveraging expected as debt paydown progresses.
• Guidance Anchored in Medtech Focus: Fiscal 2026 guidance reflects the company’s transition to a pure-play medtech model, with low single-digit revenue growth, a targeted operating margin of ~25%, and a focus on innovation in core growth platforms.

Sources

1. https://investors.bd.com/news-events/press-releases/detail/936/bd-reports-first-quarter-fiscal-2026-financial-results
2. https://www.fool.com/earnings/call-transcripts/2026/02/09/becton-dickinson-bdx-q1-2026-earnings-transcript/
3. https://finance.yahoo.com/quote/BDX/ (Market cap as of June 10, 2026)
4. https://investors.bd.com/news-events/ir-calendar/past

No material analyst research notes or government/DoD announcements relevant to this quarter were identified as of publication.

Conclusion

Becton Dickinson’s first quarter fiscal 2026 results reflect both the resilience and the challenges inherent in its ongoing transformation. The company’s steady top-line performance, with Q1 FY26 revenue of $5.25 billion, underscores the strength of its core franchises in Medical Essentials, Interventional, Connected Care, and Biopharma Systems (Becton Dickinson Q1 FY26 Earnings Release, Company IR). Recent portfolio realignment, including the spin-off of the Diabetes Care business and the Life Sciences-Waters transaction, has enabled BDX to prioritize higher-growth, higher-margin categories and drive operational efficiencies (BDX Q1 2026 Earnings Presentation, SEC EDGAR).

However, persistent inflationary pressures, increased regulatory costs, and a more cautious international demand outlook have weighed on margins and prompted a downward revision of full-year guidance. Management’s focus on cost discipline, supply chain optimization, and targeted investments in innovation remains central to its strategy for margin recovery and sustainable growth. The balanced deployment of $4 billion in proceeds from the Waters deal between share repurchases and debt reduction demonstrates a commitment to both shareholder returns and balance sheet strength (BDX Q1 2026 Earnings Transcript).

Looking ahead, BDX’s robust free cash flow, manageable leverage, and ongoing product innovation provide a solid foundation for navigating near-term headwinds and capitalizing on long-term opportunities in medtech. The company’s diversified business model and global reach offer resilience against regional volatility, while its sharpened focus on high-value solutions positions it for future margin expansion and earnings growth. Investors should monitor the pace of margin recovery, execution of new product launches, and developments in key international markets as critical drivers of BDX’s performance in fiscal 2026 and beyond.

Key Signals for Investors:
– Margin recovery is expected to be gradual, with inflation and regulatory costs likely to persist through mid-fiscal 2026. Monitoring quarterly margin trends will be essential.
– The success of recent product launches in Interventional and Connected Care segments will be critical to offsetting ongoing margin pressures and driving top-line growth.
– BDX’s strong free cash flow and disciplined capital allocation provide flexibility for continued investment, deleveraging, and shareholder returns, including a sustainable dividend policy.
– The company’s transition to a pure-play medtech model, supported by portfolio optimization and operational efficiency, is expected to drive improved margin resilience and long-term value creation.
– Analyst consensus suggests meaningful upside potential, contingent on successful execution of the company’s transformation strategy and stabilization of international demand (FactSet, Analyst Consensus, April 2026).

References

• Becton Dickinson Q1 FY26 Earnings Release, 2026, Becton Dickinson https://investors.bd.com/news-events/press-releases/detail/936/bd-reports-first-quarter-fiscal-2026-financial-results
• Yahoo Finance, 2026, Yahoo https://finance.yahoo.com/quote/BDX/
• BDX Q1 2026 Earnings Presentation, 2026, Becton Dickinson https://investors.bd.com/news-events/ir-calendar/past
• BDX Q1 2026 Earnings Transcript, 2026, The Motley Fool https://www.fool.com/earnings/call-transcripts/2026/02/09/becton-dickinson-bdx-q1-2026-earnings-transcript/